Following the decision in Italy on this matter, OCU has reported Roche and Novartis to the Spanish CNMC because the previously mentioned pharmaceutical giants may have conspired to create an artificial differentiation between their Avastin and Lucentis products (both valid for the treatment of wet macular degeneration), presenting Avastin as a more dangerous product than Lucentis, in order to influence the prescriptions of doctors and the health service. LUCENTIS is 100 times more expensive and is covered by Social Security, so the non-use of Avastin for the treatment of this disease may have been a significant waste of resources for the public health service.

Investigación por la Dirección General de Competencia de la Comisión Europea por presuntas prácticas anticompetitivas por parte de Google

Investigation by the Directorate-General for Competition for alleged anticompetitive practices by Google.

En relación a la posible manipulación del LIBOR y EURIBOR y la investigación de la Comisión Europea al respecto, OCU se dirigió al presidente de la Comisión Europea

Regarding the possible manipulation of LIBOR and EURIBOR and research of the European Commission into this issue, OCU contacted the President of the European Commission.

OCU ha detectado que en varias ciudades hay grandes coincidencias de precios que estarían poniendo de manifiesto una infracción del artículo 1 de la ley 15/2007, de defensa de la competencia, que prohíbe los acuerdos de fijación de precios entre empresas competidoras